Education
About Us
Working with TipRanks
Follow Us
Legend Biotech Corporation (LEGN)
:LEGN
LEGN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$27.34 - $59.62
Previous CloseN/A
Volume249.07K
Average Volume (3M)1.22M
Market Cap
$6.47B
Enterprise Value$5.96B
Total Cash (Recent Filing)$967.64M
Total Debt (Recent Filing)$387.92M
Price to Earnings (P/E)―
Beta0.67
Next Earnings
Nov 24, 2025EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding183,649,150
10 Day Avg. Volume959,900
30 Day Avg. Volume1,218,391
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue7.47
Enterprise Value/Gross Profit12.08
Enterprise Value/Ebitda-22.87
Forecast
1Y Price Target
$76.97Price Target Upside119.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
Bulls Say, Bears Say
Bulls Say
Financial OutlookCash and equivalents of $1 billion at the end of the second quarter provide a financial runway to profitability in 2026, potentially reducing investor concerns.
Market PositionCARVYKTI continues to solidify its position as the go-to CAR-T in myeloma, rapidly becoming entrenched as standard-of-care.
Regulatory ChangesThe FDA’s removal of REMS requirements for autologous BCMA/CD19 CAR-Ts has led to a U.S. label update shortening monitoring to two weeks and driving restrictions to two weeks, which is expected to improve patient experience and access.
Sales GrowthCarvykti's average weekly US sales during late June to early August are approximately 9% higher than the previous quarter, indicating strong growth momentum.
Bears Say
Geographical ExpansionEx-U.S. Carvykti growth was 59% quarter-over-quarter, driven by expansion in Germany, Switzerland, Austria, and Brazil, with additional growth expected following recent launches in Spain, Denmark, Sweden, Belgium, Portugal, and the private markets of Israel and the U.K., which might lead to overextension concerns.
Manufacturing CapacityManagement has reiterated guidance of manufacturing 10,000 doses by year-end with an expansion to its Raritan facility and initiation of commercial production at Tech Lane Belgium Facility coming online in 2H25, which might raise concerns about execution risks.
Legend Biotech News
LEGN FAQ
What was Legend Biotech Corporation’s price range in the past 12 months?
Legend Biotech Corporation lowest stock price was $27.34 and its highest was $59.62 in the past 12 months.
What is Legend Biotech Corporation’s market cap?
Legend Biotech Corporation’s market cap is $6.47B.
When is Legend Biotech Corporation’s upcoming earnings report date?
Legend Biotech Corporation’s upcoming earnings report date is Nov 24, 2025 which is in 88 days.
How were Legend Biotech Corporation’s earnings last quarter?
Legend Biotech Corporation released its earnings results on Aug 11, 2025. The company reported -$0.34 earnings per share for the quarter, missing the consensus estimate of -$0.113 by -$0.227.
Is Legend Biotech Corporation overvalued?
According to Wall Street analysts Legend Biotech Corporation’s price is currently Undervalued.
Does Legend Biotech Corporation pay dividends?
Legend Biotech Corporation does not currently pay dividends.
What is Legend Biotech Corporation’s EPS estimate?
Legend Biotech Corporation’s EPS estimate is -0.04.
How many shares outstanding does Legend Biotech Corporation have?
Legend Biotech Corporation has 183,649,150 shares outstanding.
What happened to Legend Biotech Corporation’s price movement after its last earnings report?
Legend Biotech Corporation reported an EPS of -$0.34 in its last earnings report, missing expectations of -$0.113. Following the earnings report the stock price went down -2.054%.
Which hedge fund is a major shareholder of Legend Biotech Corporation?
Currently, no hedge funds are holding shares in LEGN
Legend Biotech Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$76.97 (119.41% Upside)
$76.97 (119.41% Upside)
Blogger Sentiment
Bullish
LEGN Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.9%
Last 30 Days ▲ 2.3%
Last 30 Days ▲ 2.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-38.05%
12-Months-Change
Fundamentals
Return on Equity
-29.70%
Trailing 12-Months
Asset Growth
-6.02%
Trailing 12-Months
Company Description
Legend Biotech Corporation
Legend Biotech Corporation is a global biotechnology company focused on the discovery, development, and commercialization of novel cell therapies for oncology and other indications. With its headquarters in Somerset, New Jersey, Legend Biotech operates in the healthcare sector, specializing in the development of chimeric antigen receptor T-cell (CAR-T) therapies. The company's flagship product is CARVYKTI™ (ciltacabtagene autoleucel), a CAR-T therapy targeting multiple myeloma, which is developed in collaboration with Janssen Biotech, a subsidiary of Johnson & Johnson.
LEGN Company Deck
LEGN Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a predominantly positive sentiment with significant achievements in sales growth, regulatory advancements, and clinical trial results. The company's strategic expansion in global markets and operational improvements further bolster this positive outlook. However, challenges such as ongoing net losses and early-stage community oncology expansion temper the overall sentiment.View all LEGN earnings summariesLEGN Stock 12 Month Forecast
Average Price Target
$76.97
▲(119.41% Upside)
Technical Analysis
Sarepta Therapeutics
―
TG Therapeutics
―
Blueprint Medicines
―
BridgeBio Pharma
―
Revolution Medicines
―
Ownership Overview
―
Insiders
14.98% Mutual Funds
19.00% Other Institutional Investors
63.56% Public Companies and
Individual Investors